Immune Design Corporation (IMDZ) saw its loss widen to $14.45 million, or $0.57 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $12.12 million, or $0.60 a share.
Revenue during the quarter surged 80.68 percent to $2.06 million from $1.14 million in the previous year period. Gross margin for the quarter expanded 2448 basis points over the previous year period to 93.49 percent.
Operating loss for the quarter was $14.52 million, compared with an operating loss of $12.14 million in the previous year period.
"Throughout 2016, we continued enrollment of our key clinical programs, recruited senior leadership with late-stage oncology drug development expertise, and further evolved our ZVex platform to potentially enable a wider range of differentiated products. In addition, we successfully closed a follow-on offering that brought in new investors, as well as additional support from some key existing investors," said Carlos Paya, M.D., Ph.D., president and chief executive officer of Immune Design. "We look forward to a year in which clinical data begin to validate Immune Design’s approaches to treating patients."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
